Nurix Therapeutics NRIX 深 沪
已收盘 11-28 16:00:00 美东时间
17.68
+0.480
+2.79%
华盛通- 最 高17.79
- 今 开17.44
- 成交量 90.68万股
- 最 低 17.25
- 昨 收 17.20
- 总市值 17.86亿
- 52周最高 22.95
- 市盈率 静 --
- 换手率 0.90%
- 52周最低 8.18
- 委 比 -49.63%
- 总股本 1.01亿
- 历史最高 52.38
- 量 比 0.47
- 振 幅 3.14%
- 历史最低 4.22
- 每 手 1
- 风险率 3.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Securities Assumes Nurix Therapeutics at Buy, Raises Price Target to $30
Truist Securities analyst Gregory Renza assumes Nurix Therapeutics (NASDAQ:NRIX) with a Buy rating and raises Price Target to $30.
11-25 02:13
Nurix Therapeutics Appoints Roger Dansey to Board
Nurix Therapeutics ( ($NRIX) ) has issued an announcement. On November 6, 2025,...
11-10 20:52
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
13 Analysts Have This To Say About Nurix Therapeutics
Nurix Therapeutics (NASDAQ:NRIX) underwent analysis by 13 analysts in the last ...
11-04 19:45
BTIG Reiterates Buy on Nurix Therapeutics, Maintains $27 Price Target
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $27 price target.
11-04 18:40
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics announced that updated clinical data from the NX-5948-301 Phase 1a/1b trial will be presented at the 67th ASH Annual Meeting in Orlando, December 6-9, 2025. The data will feature in an oral presentation on bexobrutideg's efficacy in relapsed/refractory CLL and a poster on updated results in Waldenström macroglobulinemia. Additionally, new insights into BTK-targeted therapy resistance will be highlighted. Bexobrutideg, a BTK deg...
11-03 14:00
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics' CEO Arthur T. Sands will participate in fireside chats at Stifel 2025 Healthcare Conference in New York on November 13, and Jefferies Global Healthcare Conference in London on November 19. These sessions will be webcast live and archived for 30 days on the company's Investors page. Nurix focuses on developing targeted protein degradation medicines for cancer and inflammatory diseases, with a pipeline including degraders of BTK...
10-30 11:00
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
美股大行评级 | 上调目标价！特斯拉、赛默飞世尔、拉姆研究、波士顿科学、安诺电子、金沙集团等获众多机构评级
今日重点评级关注：摩根士丹利：维持Viking Therapeutics"超配"评级，目标价从98美元升至102美元；摩根大通：维持IDEAYA Biosciences"超配"评级，目标价从74美元升至79美元
10-24 09:51
